Issue 3: May 2018

Save the Date

ICRN Meeting
Friday, June 1

McCormick Center, Chicago
Conquer Cancer Foundation Meeting Room S403A

Click here to RSVP

Updates from the 2nd Asia-Pacific Conference
The conference was held on March 23 and 24, 2018 in collaboration with Siriraj University Hospital, Bangkok, Thailand. Approximately, 300 attendees from Thailand, China, South Korea and nearby Asian countries attended the conference.

The ICRN Executive Committee had several one day parallel meetings with our Asian collaborators to discuss areas of future collaboration.

March 22, 2018
Meeting with collaborators from Pusan National University Hospital, South Korea

Proposed projects:
  • Immune profiling study comparing Asian versus U.S. cholangiocarcinoma patients
  • Collaborate with the ICRN Translational Working Group to study the mRNA cholangiocarcinoma profiling
  • Organize multi-institutional clinical trials
March 22, 2018
Meeting with collaborators from Chiang Mai Hospital, Thailand

Proposed projects:
  • Study circulating DNA and cell-free DNA in hilar cholangiocarcinoma
  • Genomic profiling of hilar cholangiocarcinoma
  • Coordinate clinical trials studying liver transplantation for cholangiocarcinoma
  • Plan collaborative epidemiological studies
March 25, 2018
Meeting with collaborators from Second Military Hospital and Fudan University, Shanghai, China

Proposed projects:
  • Genomic profiling study comparing Chinese versus U.S. cholangiocarcinoma patients
  • Organize multi-institutional clinical trials including neoadjuvant trials for cholangiocarcinoma

ICRN Participating Centers

U.S. Centers
  • Christie NHS Foundation Trust
  • Cleveland Clinic Foundation
  • Emory University
  • Fred Hutchinson Cancer Research Center
  • Johns Hopkins University
  • Massachusetts General Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • University of California, San Francisco
  • University of Michigan
  • University of Southern California
  • University of Utah
  • University of Washington
  • Vanderbilt University
  • Virginia Mason Medical Center
International Centers
  • Chulalongkorn University [Thailand]
  • Hacettepe University cancer Institute [Turkey]
  • Hepatobiliary Medical Society Returned Scholar Association [China]
  • National Health Research Institutes, Kaoshsiung Medicine University [Taiwan]
  • Peking Union Medical College Hospital [China]
  • Princess Margaret Hospital [Canada]
  • Siriraj Hospital [Thailand]
  • University of Calgary [Canada]
  • University College of London Hospital [UK]
  • University of Amsterdam [Netherlands]

We would like to welcome our newest ICRN participating centers
  • Banner Health, Arizona
  • Eastern Hepatobiliary Surgery Hospital [China]
  • Hannover Medical School [Germany]
  • Institut Gustav Roussy [Paris]
  • National Cancer Institute Hospital [Japan]
  • Oregon Health and Sciences University Hospital
  • Pusan National University Hospital [South Korea]
  • Seoul National University College of Medicine [South Korea]
  • The University of Arizona Cancer Center
  • The University of Nottingham [London]
  • Trinity College Dublin [Ireland]
  • University Hospitals Cleveland Medical Center
  • University of Miami
  • University of Tennessee Health Science Center - Baptist Memorial Medical Group
  • Yale University

We would like to welcome our newest ICRN Executive Committee Members
Dr. Li-Tzong Chen MD, PhD.

He is Director of the National Institute of Cancer Research, National Health Research Institutes, Taiwan, where he is a Distinguished Investigator and Adjunct Attending Physician. Dr. Chen’s academic positions include Adjunct Professor at Kaohsiung Medical University and Taipei Medical University; Attending Physician at Division of Gastroenterology at Kaohsiung Medical University Hospital; and Attending Physician in the Department of Internal Medicine, National Cheng-Kung University Hospital, Taiwan. Dr. Chen is Chair of the Division of Hematology and Immunology, Minister of Sciences and Technology (MOST); and the Institution Review Board, and Protocol Review Committee of the Taiwan Cooperative Oncology Group, National Health Research Institutes.

Dr. Haitao Zhao, MD, PhD.

He is an Associate Professor and Associate Chief Physician at the Department of Liver Surgery at Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Dr. Zhao has received several funds from the Ministry of Health and awards from Beijing Municipal Government. His research interests include benign/malignant tumors in the hepatobiliary system, intrahepatic and extrahepatic cholangiocarcinoma.

Working Groups
We welcome your participation in the Working Groups of your choice. Contact Dr. Reham Abdel-Wahab at for more information.

Biorepository Working Group
Coordinates the ICRN tissue and blood banking repository.
Chair, Lewis Roberts, Mayo Clinic
Co-Chair, TBA

Genomics and Database Working Group
Initiates genomic research projects, red cap database for clinical research.
Chair, Lipika Goyal, MGH
Co-Chair, Laura Goff, Vanderbilt University

Immuno-Oncology Working Group
Coordinates IO trials, study immune biomarker expression in cholangiocarcinoma.
Chair, Nilo Azad, Johns Hopkins
Co-Chair, Katie Kelley, UCSF
Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center
Madappa Kundranda, Banner Health
Kabir Mody, Mayo Clinic
Rachna Shroff, University of Arizona

Radiation Oncology Working Group
Increases utilization of radiation for treating cholangiocarcinoma patients in Asia and Europe, radiotherapy clinical trials, retrospective studies.
Chair, Eugene Koay, MD Anderson Cancer Center
Co-Chair, Randa Tao, University of Utah

Surgical Working Group
Spearheads efforts in surgical research, liver transplantation for cholangiocarcinoma patients and international surgical trials.
Chair, Flavio Rocha, Virginia Mason University
Co-Chair, Shishir Maithel, Emory University
Yun Shin Chun, MD Anderson Cancer Center

Translational Working Group
Studies and implements translational initiatives.
Chair, Supriya Saha, Fred Hutchinson Cancer Research Center
Co-Chair, Larry Kwong, MD Anderson Cancer Center

Working Group Updates
  • Confidentiality Agreements have been executed with the Academic and Community Cancer Research United (ACCRU) and the PrECOG.
  • 3 clinical trials have been approved by sponsors but not yet activated.
  • Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for locally advanced intrahepatic cholangiocarcinoma
    Study PIs: Flavio G. Rocha and Shishir Maithel
    Study Objective:
    Primary endpoint is to assess the feasibility of this regimen in the preoperative setting.
    Secondary endpoints include resectability rate, response to chemotherapy, hepatic and extrahepatic recurrence free survival, R0 resection rates, lymph node positivity, postoperative complications, and overall survival.
    Sponsors: PrECOG, Celgene
  • Olaparib for Cholangiocarcinoma Patients with DNA Repair Genes Defects Study
    PIs: Tanios Bekaii-Saab and Daniel Ahn
    Study Objective:
    Primary endpoint is to assess tumor response rate.
    Secondary endpoints include progression free survival and overall survival.
    Sponsors: ACCRU, AstraZeneca
  • First Line Trial of Gemcitabine and Cisplatin with AG120 or INCB054828 for Advanced Cholangiocarcinoma
    Study PIs: Jonathan Whisenant and Ghassan Abou-Alfa
    Study Objective:
    Primary endpoint is to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, pharmacodynamics and the preliminary efficacy and clinical activity.
    Secondary endpoints are to evaluate progression free survival and overall survival and measure plasma 2-hydroxglutarate (2-HG) levels at baseline and after multiple doses of AG-120 study
    Sponsors: ACCRU, Incyte, Agios
  • Other data sharing projects:
    • Molecular profiling of surgically resected cholangiocarcinoma
    • Liquid biopsies to determine risk of recurrence and survival for resected cholangiocarcinoma: a potential strategy to guide adjuvant therapy
    • Cholangiocarcinoma immune profiling in Western and Asian populations
Contact Dr. Reham Abdel-Wahab at for more information about ICRN clinical trials.

Industry Engagement Initiatives

(click to enlarge)

©2006-2018 All Rights Reserved, The Cholangiocarcinoma Foundation
5526 West 13400 South, #510, Herriman, Utah 84096, U.S.A.
(888) 936-6731